https://www.jnj.com/rss-feed/all.rss RSS feed all en-US Fri, 16 Oct 2026 12:55:21 GMT https://www.jnj.com/media-center/press-releases/chmp-recommends-approval-of-johnson-johnsons-talvey-talquetamab-plus-daratumumab-in-earlier-line-treatment-of-relapsed-refractory-multiple-myeloma · If approved, TALVEY® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple myeloma as early as second line · CHMP recommendation based on Phase 3 results where talquetamab and daratumumab, with or without pomalidomide, showed progression-free survival of up to 81% and overall survival of up to 89% at 24 months1 Fri, 16 Oct 2026 12:55:21 GMT https://www.jnj.com/media-center/press-releases/chmp-recommends-approval-of-johnson-johnsons-talvey-talquetamab-plus-daratumumab-in-earlier-line-treatment-of-relapsed-refractory-multiple-myeloma https://www.jnj.com/media-center/press-releases/new-tremfya-guselkumab-study-shows-consistent-perianal-fistula-remission-across-key-crohns-disease-patient-subgroups · New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposure · Findings build on first positive results where TREMFYA achieved combined fistula remission rates of up to 28% across dosing groups · Results come from the first dedicated Phase 3 randomized, placebo-controlled trial in adults managing Crohn’s disease with perianal fistula in more than 20 years Tue, 13 Oct 2026 20:10:51 GMT https://www.jnj.com/media-center/press-releases/new-tremfya-guselkumab-study-shows-consistent-perianal-fistula-remission-across-key-crohns-disease-patient-subgroups https://www.jnj.com/media-center/press-releases/tremfya-guselkumab-demonstrated-sustained-clinical-and-endoscopic-remission-through-3-years-in-moderately-to-severely-active-crohns-disease · New long-term data showed clinical remission rates of up to 94% and endoscopic remission rates of up to 61% in adults with moderately to severely active Crohn’s disease · 88% of patients achieved 90-day corticosteroid-free clinical remission Tue, 13 Oct 2026 20:09:44 GMT https://www.jnj.com/media-center/press-releases/tremfya-guselkumab-demonstrated-sustained-clinical-and-endoscopic-remission-through-3-years-in-moderately-to-severely-active-crohns-disease https://www.jnj.com/media-center/press-releases/johnson-johnson-q3-2026-earnings-ceo-and-cfo-prepared-remarks On the Q3 2026 earnings call, Johnson & Johnson Chairman and CEO Joaquin Duato and Executive Vice President and CFO Joe Wolk discussed recent performance and long-term outlook. Tue, 13 Oct 2026 13:07:42 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-q3-2026-earnings-ceo-and-cfo-prepared-remarks https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2026 Tue, 13 Oct 2026 10:25:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2026 https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q3-2026-results-raises-2026-guidance 2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* • Tue, 13 Oct 2026 10:20:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q3-2026-results-raises-2026-guidance https://www.jnj.com/media-center/press-releases/new-johnson-johnson-icotyde-icotrokinra-long-term-data-demonstrate-robust-2-year-results-in-the-treatment-of-adults-and-adolescents-with-plaque-psoriasis · Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin at two years and a continued favorable safety profile Fri, 09 Oct 2026 11:01:23 GMT https://www.jnj.com/media-center/press-releases/new-johnson-johnson-icotyde-icotrokinra-long-term-data-demonstrate-robust-2-year-results-in-the-treatment-of-adults-and-adolescents-with-plaque-psoriasis https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-icotyde-icotrokinra-data-in-difficult-to-treat-plaque-psoriasis-with-proven-durability-through-2-years-affirming-its-use-as-a-powerful-first-line-systemic-therapy • Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body • 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112 Fri, 02 Oct 2026 10:12:35 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-icotyde-icotrokinra-data-in-difficult-to-treat-plaque-psoriasis-with-proven-durability-through-2-years-affirming-its-use-as-a-powerful-first-line-systemic-therapy https://www.jnj.com/media-center/press-releases/new-global-survey-by-johnson-johnson-finds-most-women-dont-connect-eye-health-changes-with-menopause Johnson & Johnson, Naomi Watts and the American Optometric Association encourage women to make eye health part of midlife care Thu, 01 Oct 2026 11:45:00 GMT https://www.jnj.com/media-center/press-releases/new-global-survey-by-johnson-johnson-finds-most-women-dont-connect-eye-health-changes-with-menopause https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-data-reinforcing-sustained-disease-control-and-improved-daily-function-achieved-with-imaavy-nipocalimab-aahu-in-generalized-myasthenia-gravis-gmg New two-year findings from the Phase 2/3 long-term extension demonstrate sustained disease control through two years, improvement in daily function and muscle strength, and reductions in corticosteroid use in anti-AChR+a adolescents Retrospective survey in adults identified fluctuating symptom control as a top driver for discontinuing prior advanced treatment, with most patient outcomes improving after transitioning to IMAAVY Data among 15 novel abstracts on IMAAVY to be presented at the MGFA Scientific Session during AANEM 2026 Tue, 29 Sep 2026 12:13:48 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-data-reinforcing-sustained-disease-control-and-improved-daily-function-achieved-with-imaavy-nipocalimab-aahu-in-generalized-myasthenia-gravis-gmg https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-show-significant-improvement-in-spinal-pain-and-stiffness-in-landmark-axial-psoriatic-arthritis-psa-study · Topline results show TREMFYA met the primary and major secondary endpoints of axial involvement in PsA - including spinal pain and stiffness - and demonstrated significant improvement in MRI-confirmed inflammation · First-ever study to use objective MRI assessments to confirm presence of axial involvement and demonstrate axial inflammation reduction in PsA Fri, 25 Sep 2026 11:41:08 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-show-significant-improvement-in-spinal-pain-and-stiffness-in-landmark-axial-psoriatic-arthritis-psa-study https://www.jnj.com/media-center/press-releases/single-infusion-of-carvykti-ciltacabtagene-autoleucel-delivered-five-year-treatment-free-remissions-in-50-of-patients-in-early-line-relapsed-refractory-multiple-myeloma · New results suggest earlier treatment may increase the likelihood of long-term remission · Study adds to Johnson & Johnson's overwhelming body of evidence supporting its innovative multiple myeloma therapies in second line, where earlier intervention may increase long-term remission and disease control Fri, 25 Sep 2026 11:17:30 GMT https://www.jnj.com/media-center/press-releases/single-infusion-of-carvykti-ciltacabtagene-autoleucel-delivered-five-year-treatment-free-remissions-in-50-of-patients-in-early-line-relapsed-refractory-multiple-myeloma https://www.jnj.com/media-center/press-releases/new-model-based-analysis-further-supports-the-potential-of-tecvayli-teclistamab-cqyv-plus-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-to-redefine-long-term-survival-expectations-in-early-line-relapsed-refractory-multiple-myeloma · Analysis shows ~87% of patients treated with TECVAYLI® plus DARZALEX FASPRO® as early as second line were estimated to have comparable mortality risk to the general population · A separate analysis shows the survival benefit was driven by a 90% reduction in the risk of multiple myeloma progression versus standard of care, with no significant difference in rates of non-relapse mortality · Johnson & Johnson is advancing a differentiated multiple myeloma portfolio designed to deliver deeper, more durable disease control and improve long-term outcomes for patients Wed, 23 Sep 2026 14:12:59 GMT https://www.jnj.com/media-center/press-releases/new-model-based-analysis-further-supports-the-potential-of-tecvayli-teclistamab-cqyv-plus-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-to-redefine-long-term-survival-expectations-in-early-line-relapsed-refractory-multiple-myeloma https://www.jnj.com/media-center/press-releases/depuy-synthes-showcases-next-generation-trauma-innovations-at-ota-2026 New innovations across fracture fixation, connected care, AI-assisted surgery and procedural solutions reinforce the company's leadership in trauma care. Tue, 22 Sep 2026 12:07:33 GMT https://www.jnj.com/media-center/press-releases/depuy-synthes-showcases-next-generation-trauma-innovations-at-ota-2026 https://www.jnj.com/media-center/press-releases/caplyta-lumateperone-shows-significant-and-rapid-improvement-in-bipolar-mania-in-pivotal-phase-3-study CAPLYTA® significantly reduced the signs and symptoms of acute manic episodes associated with bipolar I disorder as early as Day 3, with benefits sustained through Week 3 Results build on the established efficacy, safety and tolerability profile of CAPLYTA®, further supporting its potential to reach more patients across bipolar I and II disorders Mon, 21 Sep 2026 13:45:12 GMT https://www.jnj.com/media-center/press-releases/caplyta-lumateperone-shows-significant-and-rapid-improvement-in-bipolar-mania-in-pivotal-phase-3-study https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-plus-lazcluze-lazertinib-with-prophylactic-strategies-shows-low-rates-of-treatment-related-events-at-wclc-2026 Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis Fewer than 1% of patients discontinued treatment due to treatment-related events at one year New findings from Johnson & Johnson build on the MARIPOSA survival benefit and strengthen evidence for RYBREVANT FASPRO plus LAZCLUZE as first-line treatment Tue, 15 Sep 2026 12:30:00 GMT https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-plus-lazcluze-lazertinib-with-prophylactic-strategies-shows-low-rates-of-treatment-related-events-at-wclc-2026 https://www.jnj.com/media-center/press-releases/johnson-johnsons-2026-oncology-care-index-finds-community-oncologists-confident-in-ais-promise-but-practical-adoption-still-lags • Reported AI adoption in oncology has increased from 19% of healthcare providers across all practice settings in 2025 to 49% of community oncologists specifically in 2026 • Meanwhile use of advanced tools like predictive models remains low, at just 19%, revealing a gap between adoption and deeper implementation Mon, 14 Sep 2026 20:15:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnsons-2026-oncology-care-index-finds-community-oncologists-confident-in-ais-promise-but-practical-adoption-still-lags https://www.jnj.com/media-center/press-releases/johnson-johnsons-rybrevant-amivantamab-vmjw-plus-chemotherapy-delivers-longest-reported-median-overall-survival-in-egfr-exon-20-insertion-mutation-positive-lung-cancer RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8% Mon, 14 Sep 2026 12:30:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnsons-rybrevant-amivantamab-vmjw-plus-chemotherapy-delivers-longest-reported-median-overall-survival-in-egfr-exon-20-insertion-mutation-positive-lung-cancer https://www.jnj.com/media-center/press-releases/new-overall-survival-data-and-treatment-experience-improvements-reinforce-the-impact-of-rybrevant-amivantamab-vmjw-based-regimens-in-egfr-mutated-lung-cancer-at-wclc-2026 Presidential Symposium to feature final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC Additional findings show low rates of key treatment-related events with subcutaneous RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) and prophylactic strategies Fri, 11 Sep 2026 21:00:00 GMT https://www.jnj.com/media-center/press-releases/new-overall-survival-data-and-treatment-experience-improvements-reinforce-the-impact-of-rybrevant-amivantamab-vmjw-based-regimens-in-egfr-mutated-lung-cancer-at-wclc-2026 https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-ce-marking-for-acuvue-oasys-max-reusable-contact-lenses New 2-week reusable contact lens brings advanced ACUVUE OASYS MAX technologies to deliver superior comfort and visual clarity to patients, even at day 14*†i Expands the ACUVUE OASYS MAX portfolio with an advanced option for reusable contact lens wearers Designed to meet the growing demand for lasting comfort and clear vision in today’s screen-intensive world *†1 Thu, 10 Sep 2026 11:45:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-ce-marking-for-acuvue-oasys-max-reusable-contact-lenses https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-data-at-ims-2026-highlighting-its-industry-leading-multiple-myeloma-portfolio-with-the-goal-of-advancing-the-potential-for-cure · 35+ abstracts demonstrate new findings across DARZALEX®, TECVAYLI® plus DARZALEX FASPRO®, CARVYKTI®, TALVEY®, and the investigational trispecific antibody ramantamig, highlighting the potential of early intervention with immune-based therapies to transform outcomes across the patient journey · With decades of leadership in multiple myeloma, Johnson & Johnson continues to drive innovation throughout the patient journey, from market-leading backbone therapies to next-generation immune-based approaches Wed, 09 Sep 2026 12:30:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-data-at-ims-2026-highlighting-its-industry-leading-multiple-myeloma-portfolio-with-the-goal-of-advancing-the-potential-for-cure https://www.jnj.com/media-center/press-releases/johnson-johnson-spotlights-new-neuropsychiatry-data-across-bipolar-mania-depression-and-schizophrenia-at-psych-congress-2026 First presentation of pivotal Phase 3 CAPLYTA® data in adults with bipolar mania underscores the asset’s potential across mood disorders New SPRAVATO® analyses and schizophrenia research emphasize a focus on complex, high-burden neuropsychiatric conditions Tue, 08 Sep 2026 12:00:07 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-spotlights-new-neuropsychiatry-data-across-bipolar-mania-depression-and-schizophrenia-at-psych-congress-2026 https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-deutsche-bank-2026-healthcare-summit Wed, 02 Sep 2026 20:07:36 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-deutsche-bank-2026-healthcare-summit https://www.jnj.com/media-center/press-releases/johnson-johnson-host-investor-conference-call-on-third-quarter-results Mon, 31 Aug 2026 21:02:23 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-host-investor-conference-call-on-third-quarter-results https://www.jnj.com/media-center/press-releases/fda-approves-imaavy-nipocalimab-aahu-as-first-ever-treatment-for-warm-autoimmune-hemolytic-anemia-waiha-representing-a-landmark-advancement-for-patients · IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function · Warm autoimmune hemolytic anemia is a rare, life-threatening disease in which autoantibodies cause the destruction of red blood cells, leading to severe anemia and debilitating fatigue · The approval is based on the pivotal Phase 2/3 study which demonstrated durable hemoglobin responsea · A mean increase in hemoglobin of 1 g/dL at Week 1b and improvement in FACIT-Fatiguec score at Week 24 were observed in IMAAVY-treated patientsd Mon, 24 Aug 2026 22:26:56 GMT https://www.jnj.com/media-center/press-releases/fda-approves-imaavy-nipocalimab-aahu-as-first-ever-treatment-for-warm-autoimmune-hemolytic-anemia-waiha-representing-a-landmark-advancement-for-patients